Looking Into Vivos Therapeutics's Return On Capital Employed
Portfolio Pulse from Benzinga Insights
Vivos Therapeutics (NASDAQ:VVOS) reported Q1 sales of $3.86 million and a loss of $1.70 million, despite a 72.03% increase in earnings. The company posted a negative Return on Capital Employed (ROCE) of -0.24%, suggesting inefficient capital allocation. Vivos Therapeutics' Q1 earnings per share of $-0.07 beat analyst predictions of $-0.18.
June 09, 2023 | 2:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Vivos Therapeutics reported Q1 sales of $3.86 million and a loss of $1.70 million, with a negative ROCE of -0.24%, suggesting inefficient capital allocation. The company's Q1 EPS of $-0.07 beat analyst predictions of $-0.18.
Vivos Therapeutics' Q1 earnings report shows a negative ROCE of -0.24%, indicating inefficient capital allocation. However, the company's Q1 EPS of $-0.07 beat analyst predictions of $-0.18, which could have a neutral impact on the stock price in the short term. The negative ROCE suggests potential long-term concerns, but the better-than-expected EPS may offset this in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100